A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

You may be eligible if

• 1. Diagnosis of proven or probable Invasive mold infection (IMI) defined in accordance with the Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the EORTC/MSGERC as adapted for this study and caused by Aspergillus spp. (in patients with limited treatment options), Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multi-drug resistant molds.
• 2. Patient's condition allows for appropriate infection source control measures.
• Main Exclusion Critera:
• 1. Refractory hematologic malignancy.
• 2. Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
• 3. Coronavirus disease 2019 (COVID-19) associated mucormycosis.
• 4. Invasive fungal disease caused by more than one fungal pathogen is not permitted in Cohort A but is permitted in Cohort B.
• 5. Patients with a Karnofsky Performance Status \< 20 at Screening.
• 6. Requirement, or anticipated requirement, for hemodialysis, peritoneal dialysis, or hemofiltration.
• 7. Patients with known human immunodeficiency virus infection.
• 8. Ongoing neurological disorders.
• 9. Patients receiving hospice/comfort care only.
• 10. Other medical or psychiatric condition.
• 11. Current use of any prohibited concomitant medication(s).
• 12. Current/ previous administration of an investigational drug within 30 days.
• 13. Prior enrollment in this or any previous study of fosmanogepix.
• 14. Moderate or severe hepatic impairment.
• 15. Patient who is pregnant or lactating.
• 16. Known hypersensitivity to fosmanogepix, manogepix, or any of their excipients.